Laurus Labs Ltd (LAURUSLABS) Q1 FY27 Results Analysis: EBITDA Margin Expands 715 bps, Revenue Grows 29%

Laurus Labs Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 2,026.31 Cr (+29.10% YoY) and PAT growth of +125.49% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quarter Snapshot

Laurus Labs delivered a strong Q1 with 29% revenue growth, 715 bps EBITDA margin expansion to 31.5%, and PAT more than doubling. Subsidiary profitability surged, and regulatory risk is mitigated by a zero-observation EIR. However, the absence of management guidance and segment-level disclosure limits visibility into the sustainability of the CDMO and ARV trends.

Key Investment Insights

Key Positives

• Revenue grew 29.1% YoY to Rs.2,026.31 Cr, with sequential acceleration to 11.9% QoQ.
• EBITDA margin expanded 715 bps YoY to 31.50%, with every cost head improving as a percentage of revenue.
• PAT attributable to equity holders rose 125.5% YoY to Rs.367.60 Cr, and EPS doubled to Rs.6.81.
• Subsidiary PAT contribution surged from Rs.5.08 Cr to Rs.77.64 Cr, indicating strong profitability in regulated generics or Laurus Bio.
• Finance costs fell 18% YoY despite slight QoQ increase, suggesting debt reduction or lower rates.
• Clean audit opinion with no exceptional items or qualifications.